Home / Tag: Arcturus Therapeutics

Tag Archives: Arcturus Therapeutics

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810

Treatment of Ornithine Transcarbamylase (OTC) Deficiency San Diego CA—Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards ...

Read More »

Arcturus Therapeutics to Present Data for ARCT-810 and the Arcturus mRNA + LUNAR Technology Platform

Presentation will take place at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics San Diego CA— Arcturus Therapeutics Ltd. (NASDAQ: ARCT) (the “Company”), a leading messenger ...

Read More »

Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

San Diego CA—  Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,  liver and respiratory diseases with ...

Read More »

Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer

San Diego CA— Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic, and respiratory diseases ...

Read More »